Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures

被引：10
作者：
Thoueille, Paul [1 ,2 ]
Cavassini, Matthias [2 ,3 ]
Guidi, Monia [1 ,2 ,4 ,5 ]
Buclin, Thierry [1 ,2 ]
Girardin, Francois R. [1 ,2 ]
Decosterd, Laurent A. [1 ,2 ]
Marzolini, Catia [1 ,6 ,7 ,8 ,9 ]
机构：
[1] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Lausanne, Switzerland
[2] Univ Lausanne, Lausanne, Switzerland
[3] Lausanne Univ Hosp, Dept Med, Serv Infect Dis, Lausanne, Switzerland
[4] Lausanne Univ Hosp, Ctr Res & Innovat Clin Pharmaceut Sci, Lausanne, Switzerland
[5] Univ Lausanne, Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland
[6] Univ Basel, Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland
[7] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, England
[8] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Rue Bugnon 17, Lausanne, Switzerland
[9] Univ Lausanne, Rue Bugnon 17, Lausanne, Switzerland
来源：
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 02期
基金：
瑞士国家科学基金会;
关键词：
cabotegravir; guidance; long-acting; rilpivirine; TDM; ADULTS;
D O I：
10.1093/ofid/ofae023
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The interpretation of long-acting cabotegravir and rilpivirine concentrations is complicated by the lack of consensus on the threshold to consider. Building on real-world therapeutic drug monitoring data and documented virologic failures, this article provides a reappraisal of the existing thresholds and guidance for the interpretation of cabotegravir and rilpivirine concentrations. There is no established threshold for the interpretation of long-acting cabotegravir/rilpivirine concentrations. Building on real-world TDM data and documented virologic failures, this article provides a reappraisal of the existing thresholds, and guidance for the interpretation of cabotegravir and rilpivirine concentrations.
引用
收藏
页数：4
相关论文
共 13 条
  • [1] Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals
    Aouri, Manel
    Barcelo, Catalina
    Guidi, Monia
    Rotger, Margalida
    Cavassini, Matthias
    Hizrel, Cedric
    Buclin, Thierry
    Decosterd, Laurent A.
    Csajka, Chantal
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (01)
  • [2] Bailon L., 2023, 19 EUROPEAN AIDS C
  • [3] Ehret R., 2023, 19 EUROPEAN AIDS C
  • [4] Han K., 2021, HIV RES PREVENTION H
  • [5] Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
    Landovitz, Raphael J.
    Li, Sue
    Eron Jr, Joseph J.
    Grinsztejn, Beatriz
    Dawood, Halima
    Liu, Albert Y.
    Magnus, Manya
    Hosseinipour, Mina C.
    Panchia, Ravindre
    Cottle, Leslie
    Chau, Gordon
    Richardson, Paul
    Marzinke, Mark A.
    Eshleman, Susan H.
    Kofron, Ryan
    Adeyeye, Adeola
    Burns, David
    Rinehart, Alex R.
    Margolis, David
    Cohen, Myron S.
    McCauley, Marybeth
    Hendrix, Craig W.
    [J]. LANCET HIV, 2020, 7 (07): : E472 - E481
  • [6] Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
    Margolis, David A.
    Brinson, Cynthia C.
    Smith, Graham Hr
    de Vente, Jerome
    Hagins, Debbie P.
    Eran, Joseph J.
    Griffith, Sandy K.
    St Clair, Marty H.
    Stevens, Marita C.
    Williams, Peter E.
    Ford, Susan L.
    Stand, Britt S.
    Bomar, Melinda M.
    Hudson, Krischan J.
    Smith, Kimberly Y.
    Spreen, William R.
    [J]. LANCET INFECTIOUS DISEASES, 2015, 15 (10) : 1145 - 1155
  • [7] Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir plus Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure
    Orkin, Chloe
    Schapiro, Jonathan M.
    Perno, Carlo F.
    Kuritzkes, Daniel R.
    Patel, Parul
    DeMoor, Rebecca
    Dorey, David
    Wang, Yongwei
    Han, Kelong
    Van Eygen, Veerle
    Crauwels, Herta
    Ford, Susan L.
    Latham, Christine L.
    St. Clair, Marty
    Polli, Joseph W.
    Vanveggel, Simon
    Vandermeulen, Kati
    D'Amico, Ronald
    Garges, Harmony P.
    Zolopa, Andrew
    Spreen, William R.
    van Wyk, Jean
    Cutrell, Amy G.
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, 77 (10) : 1423 - 1431
  • [8] Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
    Orkin, Chloe
    Morell, Enrique Bernal
    Tan, Darrell H. S.
    Katner, Harold
    Stellbrink, Hans-Juergen
    Belonosova, Elena
    DeMoor, Rebecca
    Griffith, Sandy
    Thiagarajah, Shanker
    Van Solingen-Ristea, Rodica
    Ford, Susan L.
    Crauwels, Herta
    Patel, Parul
    Cutrell, Amy
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Birmingham, Eileen
    St Clair, Marty
    Spreen, William R.
    D'Amico, Ronald
    [J]. LANCET HIV, 2021, 8 (11): : E668 - E678
  • [9] Long-acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 (HIV-1) Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-label, Phase 3b, Noninferiority Study
    Overton, Edgar T.
    Richmond, Gary
    Rizzardini, Giuliano
    Thalme, Anders
    Girard, Pierre-Marie
    Wong, Alexander
    Porteiro, Norma
    Swindells, Susan
    Reynes, Jacques
    Noe, Sebastian
    Harrington, Conn
    Espanol, Carlos Martin
    Acuipil, Carolina
    Aksar, Asma
    Wang, Yuanyuan
    Ford, Susan L.
    Crauwels, Herta
    van Eygen, Veerle
    Van Solingen-Ristea, Rodica
    Latham, Christine L.
    Thiagarajah, Shanker
    D'Amico, Ronald
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Spreen, William R.
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, 76 (09) : 1646 - 1654
  • [10] Rubenstein E., 2023, 19 EUROPEAN AIDS C
12